{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:40:04Z","timestamp":1792435204336,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00542-7","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:44:58Z","timestamp":1784724298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Performance status and outcomes in patients with cancer receiving thromboprophylaxis: a subanalysis of the AVERT trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Nicola","family":"Potere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeeta","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Lazo-Langner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Tagalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"7","key":"542_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","volume":"1","author":"HJ West","year":"2015","unstructured":"West HJ, Jin JO. Performance Status in Patients With Cancer. JAMA Oncol. 2015;1(7):998. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3113.","journal-title":"JAMA Oncol"},{"issue":"6","key":"542_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"542_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/oxfordjournals.annonc.a057981","volume":"2","author":"F Roila","year":"1991","unstructured":"Roila F, Lupattelli M, Sassi M, et al. Intra and interobserver variability in cancer patients\u2019 performance status assessed according to Karnofsky and ECOG scales. Ann Oncol Off J Eur Soc Med Oncol. 1991;2(6):437\u20139. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a057981.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"542_CR4","doi-asserted-by":"publisher","first-page":"1331246","DOI":"10.3389\/fmed.2024.1331246","volume":"11","author":"A Topcu","year":"2024","unstructured":"Topcu A, Yasin AI, Besiroglu M, et al. Prevalence and co-incidence of geriatric syndromes according to the ECOG performance status in older cancer patients. Front Med. 2024;11:1331246. https:\/\/doi.org\/10.3389\/fmed.2024.1331246.","journal-title":"Front Med"},{"issue":"24","key":"542_CR5","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(24):2595\u2013603. https:\/\/doi.org\/10.1200\/JCO.2013.54.8347.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"542_CR6","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(22):2326\u201347. https:\/\/doi.org\/10.1200\/JCO.2018.78.8687.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"542_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","volume":"3","author":"L Gervaso","year":"2021","unstructured":"Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2021;3(2):173\u201390. https:\/\/doi.org\/10.1016\/j.jaccao.2021.03.001.","journal-title":"JACC CardioOncology"},{"issue":"1","key":"542_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primer. 2022;8(1):11. https:\/\/doi.org\/10.1038\/s41572-022-00336-y.","journal-title":"Nat Rev Dis Primer"},{"issue":"6","key":"542_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","volume":"43","author":"L Girardi","year":"2023","unstructured":"Girardi L, Wang TF, Ageno W, Carrier M. Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism. Arterioscler Thromb Vasc Biol. 2023;43(6):824\u201331. https:\/\/doi.org\/10.1161\/ATVBAHA.123.318779.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"542_CR10","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959\u201369. https:\/\/doi.org\/10.1182\/blood.2020007338.","journal-title":"Blood"},{"issue":"8","key":"542_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380(8):711\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1814468.","journal-title":"N Engl J Med"},{"issue":"8","key":"542_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1814630.","journal-title":"N Engl J Med"},{"issue":"5","key":"542_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461.","journal-title":"J Clin Oncol"},{"issue":"4","key":"542_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442.","journal-title":"Blood Adv"},{"issue":"5","key":"542_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol Off J Eur Soc Med Oncol. 2023;34(5):452\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"542_CR16","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1002\/onco.13569","volume":"26","author":"AA Khorana","year":"2021","unstructured":"Khorana AA, DeSancho MT, Liebman H, Rosovsky R, Connors JM, Zwicker J. Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist. 2021;26(1):e2\u20137. https:\/\/doi.org\/10.1002\/onco.13569.","journal-title":"Oncologist"},{"issue":"2","key":"542_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1055\/a-2347-6507","volume":"45","author":"C Englisch","year":"2025","unstructured":"Englisch C, Vladic N, Ay C. Bleeding Risk in Patients with Cancer. Hamostaseologie. 2025;45(2):188\u2013203. https:\/\/doi.org\/10.1055\/a-2347-6507.","journal-title":"Hamostaseologie"},{"issue":"1","key":"542_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/eurjpc\/zwaa167","volume":"29","author":"D Richter","year":"2022","unstructured":"Richter D, Guasti L, Walker D, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol. 2022;29(1):216\u201327. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa167.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"542_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaccao.2024.02.001","volume":"6","author":"D Ioffe","year":"2024","unstructured":"Ioffe D, Bhatia-Patel SC, Gandhi S, Hamad EA, Dotan E. Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer. JACC CardioOncology. 2024;6(2):143\u201358. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.001.","journal-title":"JACC CardioOncology"},{"issue":"41","key":"542_CR20","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"1","key":"542_CR21","doi-asserted-by":"publisher","first-page":"1600282","DOI":"10.1183\/13993003.00282-2016","volume":"49","author":"C Font","year":"2017","unstructured":"Font C, Carmona-Bayonas A, Beato C, et al. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J. 2017;49(1):1600282. https:\/\/doi.org\/10.1183\/13993003.00282-2016.","journal-title":"Eur Respir J"},{"issue":"11","key":"542_CR22","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1111\/jth.15489","volume":"19","author":"A Maraveyas","year":"2021","unstructured":"Maraveyas A, Kraaijpoel N, Bozas G, et al. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. J Thromb Haemost JTH. 2021;19(11):2791\u2013800. https:\/\/doi.org\/10.1111\/jth.15489.","journal-title":"J Thromb Haemost JTH"},{"issue":"4","key":"542_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jaccao.2022.07.008","volume":"4","author":"IT Farmakis","year":"2022","unstructured":"Farmakis IT, Barco S, Mavromanoli AC, Konstantinides SV, Valerio L. Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism. JACC CardioOncology. 2022;4(4):507\u201318. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.008.","journal-title":"JACC CardioOncology"},{"issue":"4","key":"542_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost JTH. 2005;3(4):692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost JTH"},{"issue":"11","key":"542_CR25","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost JTH. 2015;13(11):2119\u201326. https:\/\/doi.org\/10.1111\/jth.13140.","journal-title":"J Thromb Haemost JTH"},{"issue":"2","key":"542_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1634\/theoncologist.2017-0205","volume":"23","author":"NM Kuderer","year":"2018","unstructured":"Kuderer NM, Poniewierski MS, Culakova E, et al. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). Oncologist. 2018;23(2):247\u201355. https:\/\/doi.org\/10.1634\/theoncologist.2017-0205.","journal-title":"Oncologist"},{"issue":"9","key":"542_CR27","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1007\/s00520-021-06139-3","volume":"29","author":"DC Guven","year":"2021","unstructured":"Guven DC, Aksun MS, Sahin TK, et al. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Support Care Cancer. 2021;29(9):5417\u201323. https:\/\/doi.org\/10.1007\/s00520-021-06139-3.","journal-title":"Support Care Cancer"},{"issue":"7","key":"542_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamainternmed.2025.1109","volume":"185","author":"S Bea","year":"2025","unstructured":"Bea S, Iyer GS, Kim DH, et al. Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism. JAMA Intern Med. 2025;185(7):837\u201346. https:\/\/doi.org\/10.1001\/jamainternmed.2025.1109.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"542_CR29","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.7326\/M20-7141","volume":"174","author":"DH Kim","year":"2021","unstructured":"Kim DH, Pawar A, Gagne JJ, et al. Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation: A Cohort Study. Ann Intern Med. 2021;174(9):1214\u201323. https:\/\/doi.org\/10.7326\/M20-7141.","journal-title":"Ann Intern Med"},{"issue":"12","key":"542_CR30","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1111\/jgs.18001","volume":"70","author":"M Candeloro","year":"2022","unstructured":"Candeloro M, Di Nisio M, Potere N, et al. Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants. J Am Geriatr Soc. 2022;70(12):3503\u201312. https:\/\/doi.org\/10.1111\/jgs.18001.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"542_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/ageing\/afaa265","volume":"50","author":"C Wilkinson","year":"2021","unstructured":"Wilkinson C, Clegg A, Todd O, et al. Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study. Age Ageing. 2021;50(3):772\u20139. https:\/\/doi.org\/10.1093\/ageing\/afaa265.","journal-title":"Age Ageing"},{"key":"542_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.thromres.2024.02.023","volume":"236","author":"Y Ogihara","year":"2024","unstructured":"Ogihara Y, Yamashita Y, Morimoto T, et al. Fragility and long-term clinical outcomes in patients with venous thromboembolism receiving direct oral anticoagulants: From the COMMAND VTE REGISTRY-2. Thromb Res. 2024;236:191\u2013200. https:\/\/doi.org\/10.1016\/j.thromres.2024.02.023.","journal-title":"Thromb Res"},{"issue":"1","key":"542_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/cancers11010048","volume":"11","author":"F Scott\u00e9","year":"2019","unstructured":"Scott\u00e9 F, Leroy P, Chastenet M, Aumont L, Benatar V, Elalamy I. Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. Cancers. 2019;11(1):48. https:\/\/doi.org\/10.3390\/cancers11010048.","journal-title":"Cancers"},{"issue":"5","key":"542_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","volume":"3","author":"O Leiva","year":"2021","unstructured":"Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DL. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2021;3(5):619\u201334. https:\/\/doi.org\/10.1016\/j.jaccao.2021.08.011.","journal-title":"JACC CardioOncology"},{"key":"542_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","volume":"112","author":"MC Vedovati","year":"2023","unstructured":"Vedovati MC, Giustozzi M, Munoz A, et al. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. Eur J Intern Med. 2023;112:29\u201336. https:\/\/doi.org\/10.1016\/j.ejim.2023.02.003.","journal-title":"Eur J Intern Med"},{"key":"542_CR36","doi-asserted-by":"publisher","first-page":"ehaf453","DOI":"10.1093\/eurheartj\/ehaf453","volume":"22","author":"F Khan","year":"2025","unstructured":"Khan F, Tritschler T, Marx CE, et al. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. Eur Heart J Published online June. 2025;22:ehaf453. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf453.","journal-title":"Eur Heart J Published online June"},{"issue":"5","key":"542_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jacc.2021.11.029","volume":"79","author":"N Ijaz","year":"2022","unstructured":"Ijaz N, Buta B, Xue QL, et al. Interventions for Frailty Among Older Adults With Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(5):482\u2013503. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.029.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"542_CR38","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","volume":"139","author":"SC Gilchrist","year":"2019","unstructured":"Gilchrist SC, Barac A, Ades PA, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2019;139(21):e997\u20131012. https:\/\/doi.org\/10.1161\/CIR.0000000000000679.","journal-title":"Circulation"},{"issue":"10","key":"542_CR39","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jamacardio.2023.1634","volume":"8","author":"DH Kim","year":"2023","unstructured":"Kim DH, Zhong L, Rich MW. Frailty-Guided Management of Cardiovascular Disease\u2014From Clinical Trials to Clinical Practice. JAMA Cardiol. 2023;8(10):897. https:\/\/doi.org\/10.1001\/jamacardio.2023.1634.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"542_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","volume":"6","author":"T Fujisaki","year":"2024","unstructured":"Fujisaki T, Sueta D, Yamamoto E, et al. Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer: A Systematic Review and Meta-Analysis. JACC CardioOncology. 2024;6(1):99\u2013113. https:\/\/doi.org\/10.1016\/j.jaccao.2023.10.009.","journal-title":"JACC CardioOncology"},{"issue":"14","key":"542_CR41","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","volume":"392","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D, et al. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2025;392(14):1363\u201373. https:\/\/doi.org\/10.1056\/NEJMoa2416112.","journal-title":"N Engl J Med"},{"key":"542_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2023.05.008","volume":"228","author":"J Goedegebuur","year":"2023","unstructured":"Goedegebuur J, Abbel D, Accassat S, et al. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool. Thromb Res. 2023;228:54\u201360. https:\/\/doi.org\/10.1016\/j.thromres.2023.05.008.","journal-title":"Thromb Res"},{"issue":"5","key":"542_CR43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3390\/cancers12051187","volume":"12","author":"RD Dolan","year":"2020","unstructured":"Dolan RD, Daly LE, Simmons CP, et al. The Relationship between ECOG-PS, mGPS, BMI\/WL Grade and Body Composition and Physical Function in Patients with Advanced Cancer. Cancers. 2020;12(5):1187. https:\/\/doi.org\/10.3390\/cancers12051187.","journal-title":"Cancers"},{"issue":"5","key":"542_CR44","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1001\/jamaoncol.2024.0023","volume":"10","author":"K Ito","year":"2024","unstructured":"Ito K, Suzuki Y, Sakaguchi T, et al. Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer. JAMA Oncol. 2024;10(5):648\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0023.","journal-title":"JAMA Oncol"},{"issue":"1","key":"542_CR45","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2666-7568(20)30036-2","volume":"2","author":"WK Soo","year":"2021","unstructured":"Soo WK, King M, Pope A, et al. The Elderly Functional Index (ELFI), a patient-reported outcome measure of functional status in patients with cancer: a multicentre, prospective validation study. Lancet Healthy Longev. 2021;2(1):e24\u201333. https:\/\/doi.org\/10.1016\/S2666-7568(20)30036-2.","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"542_CR46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamaoncol.2020.6736","volume":"7","author":"MV Garcia","year":"2021","unstructured":"Garcia MV, Agar MR, Soo WK, To T, Phillips JL. Screening Tools for Identifying Older Adults With Cancer Who May Benefit From a Geriatric Assessment: A Systematic Review. JAMA Oncol. 2021;7(4):616\u201327. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6736.","journal-title":"JAMA Oncol"},{"issue":"9","key":"542_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.clon.2020.06.016","volume":"32","author":"R Simcock","year":"2020","unstructured":"Simcock R, Wright J. Beyond Performance Status. Clin Oncol R Coll Radiol G B. 2020;32(9):553\u201361. https:\/\/doi.org\/10.1016\/j.clon.2020.06.016.","journal-title":"Clin Oncol R Coll Radiol G B"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00542-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:02:44Z","timestamp":1792432964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00542-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00542-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The AVERT trial (ClinicalTrials.gov number, NCT02048865) was approved by the institutional research ethics board or ethics committee at each participating center, and all participants provided written informed consent before enrollment. The present study is a post hoc analysis of previously collected AVERT trial data and did not involve additional patient contact or study procedures.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N. Potere has received, outside of the present work, research fellowships and awards from the International Society on Thrombosis and Haemostasis (ISTH), the Canadian Venous Thromboembolism Research Network (CanVECTOR) and the Italian Society for the Study on Thrombosis and Haemostasis, and research funding, paid to his institution, from the International Network of VENous Thromboembolism Clinical Research Networks (INVENT) and the ISTH Scientific and Standardization Committee. M.D.N. reports personal fees as invited speaker from Werfen, Mylan, Leo Pharma and Pfizer, and institutional funding from Leo Pharma outside of the present work. A Lazo-Langner has received research funding from Regeneron Pharmaceuticals. M. Carrier has received research funding from BMS, Pfizer, and Leo Pharma, and honoraria from Bayer, Pfizer, BMS, Servier, and Leo Pharma. The other authors have no relevant conflicts of interest to disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}